Enhancing Accessibility to Clinical Trials for Cardiomyopathy Patients

Despite significant scientific progress in cardiovascular medicine, many individuals living in rural and underserved communities continue to face obstacles in accessing advanced therapies, such as gene editing for cardiomyopathy. According to a 2020 American Heart Association advisory, these disparities hinder equitable healthcare delivery. To bridge these gaps, the American Heart Association is leveraging its 'Get With The Guidelines' data to support populations that are often underrepresented in clinical research. This program aligns hospitals with current evidence-based guidelines and precision measurement tools to elevate care quality.

Aiming to improve diagnosis, treatment, and outcomes for cardiomyopathy, the organization has launched an initiative focused on gene-editing therapies for transthyretin amyloid cardiomyopathy (ATTR-CM). This progressive and often underdiagnosed heart condition involves abnormal accumulation of transthyretin protein in the heart, disrupting its ability to relax and fill properly, which can eventually lead to heart failure.

The initiative seeks to close knowledge gaps, raise awareness, and improve access to early diagnosis and emerging treatments regardless of geographical location through research, education, and community outreach. With financial backing from Intellia Therapeutics, the program emphasizes increasing understanding of gene editing, advancing research, and expanding clinical trial opportunities among traditionally excluded populations.

According to Dr. Michelle Kittleson, the campaign aims to ensure that the latest medical innovations are accessible to all, fostering trust and participation across diverse communities. The initiative features a comprehensive education campaign, including a series of webinars, with the first scheduled for June 18, titled 'Understanding Amyloidosis & Emerging Therapeutic Frontiers.' It will feature leading experts in cardiology and gene therapy.

Additional efforts include enhancing patient identification systems, developing referral networks, and creating tools that utilize clinical data to identify eligible trial participants. These steps are designed to improve patient enrollment in innovative therapies and clinical research, ultimately contributing to better care and outcomes for those affected by cardiomyopathy.

This ongoing effort aligns with the American Heart Association’s broader mission to improve cardiovascular health equity and ensure that advancements in treatment reach all populations, especially those currently underserved.